Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Rescue with obinutuzumab and daratumumab as combined B cell/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence.

Author information

Affiliations

  • 1. Renal Transplantation Center "A. Vercellone," Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital and University of Turin, Corso Bramante, Turin, Italy.
      Authors
    • Randone P 1
    • Sanna E 1
    • Dolla C 1
    • Gallo E 1
    • Mingozzi S 1
    • Tarragoni R 1
    • Torazza MC 1
    • Niarchos A 1
    • Mella A 1
    • Manzione AM 1
    • Deambrosis I 1
    • Giraudi R 1
    • Biancone L 1
    (13 authors)
  • 2. Pathology Unit, University of Turin, Città Della Salute e Della Scienza, Turin, Italy.
      Authors
    • Barreca A 2
    (1 author)

ORCIDs linked to this article

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 17 Jul 2024, 24(10):1896-1900
https://doi.org/10.1016/j.ajt.2024.06.010 PMID: 39029875 

Abstract 

The recurrence of primary focal segmental glomerulosclerosis (FSGS) after kidney transplantation is associated with a high graft loss rate with standard treatments based on plasmapheresis with/without rituximab. We present 2 consecutive cases of nongenetic early severe recurrent FSGS refractory to rituximab and anti-interleukin 1 treatment and with a partial response to plasmapheresis. Case 1 was a 22-year-old man who was rescue-treated for recurrence 36 weeks after transplantation with obinutuzumab (1000 mg/1.73 m2, 1 dose) and daratumumab (18 mg/kg each dose, 8 doses), resulting in plasmapheresis discontinuation and a drop of proteinuria from 29 to 2.3 g/d. Proteinuria increased with circulating CD38+ plasma cells and responded to an additional daratumumab dose. Currently, the proteinuria is 1.8 g/d, 14.5 months after discontinuing plasmapheresis and starting obinutuzumab and daratumumab therapy. Case 2 was a 15-year-old girl who was plasmapheresis dependent with 2 g/d proteinuria 82 weeks after transplantation, with a Tesio catheter in the right jugular vein as the only possible vascular access. After treatment with obinutuzumab and daratumumab (1 dose each), she achieved stable complete remission (0.3 g/d proteinuria) with persistent plasmapheresis discontinuation. These cases suggest the potential of combining obinutuzumab with daratumumab for the treatment of recurrent FSGS.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.ajt.2024.06.010

Citations & impact 

Impact metrics

1
Citation
Jump to Citations

Alternative metrics

Altmetric item for https://www.altmetric.com/details/169719819
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/169719819

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Fondazione CRT

    Ministero dell'Istruzione dell'Universita e della Ricerca (1)

    Ministero dell’Istruzione, dell’Università e della Ricerca

      University of Turin